vTv Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VTVT research report →
Range $49 – $58
Price Chart
About the company
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes.
- CEO
- Paul J. Sekhri
- IPO
- 2015
- Employees
- 26
- HQ
- High Point, NC, US
Get TickerSpark's AI analysis on VTVT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $82.01M
- P/E
- 1577.50
- PEG
- 22.67
- P/S
- 2.24
- P/B
- 2.95
- EV/EBITDA
- 21.70
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -8.26%
- Net Margin
- 6.11%
- ROE
- 3.96%
- ROIC
- -3.31%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-32,808,000
- Net Income
- $-26,974,000-46.1%
- EPS
- $-3.20+0.0%
- OCF Growth
- +0.2%
- FCF Growth
- +0.2%
- 52W High
- $44.00
- 52W Low
- $14.00
- 50D MA
- $33.79
- 200D MA
- $32.91
- Beta
- 0.25
- RSI (14)
- 41
- Avg Volume
- 56.19K
No earnings-call transcripts are available for VTVT yet.
- Free Float
- 54.0%
- Shares Outstanding
- 2.62M
- Float Shares
- 1.41M
of shares held by institutions
35 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Samsara Biocapital, LLC | 298.50K | 0 |
| Fmr LLC | 260.39K | ▼ 8.46K |
| Millennium Management LLC | 206.29K | ▲ 206.29K |
| Siren, L.L.C. | 163.00K | 0 |
| Baker Bros. Advisors LP | 148.31K | 0 |
| Vanguard Group Inc | 83.40K | ▲ 36.41K |
| Geode Capital Management, LLC | 32.89K | ▲ 4.69K |
| Northern Trust Corp | 18.05K | ▲ 2.00K |
| Vanguard Fiduciary Trust Co | 16.13K | ▲ 16.13K |
| 683 Capital Management, LLC | 16.00K | ▼ 2.27K |
| Marshall Wace, Llp | 13.39K | ▲ 13.39K |
| Goldman Sachs Group Inc | 13.35K | ▲ 7.82K |
Held by 26 ETFs
Biggest fund positions in VTVT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 26, 26 | BAKER BROS. ADVISORS LP | other | 6,000 |
| Jun 26, 26 | SPIEGELMAN DANIEL K | other | 6,000 |
| Jun 26, 26 | AKKARAJU SRINIVAS | other | 6,000 |
| Jun 26, 26 | Al-Marzooqi Fahed | other | 6,000 |
| Jun 26, 26 | Phillips Anne M. | other | 6,000 |
| Feb 17, 26 | Tung Michael Stephen | other | 44,969 |
| Feb 17, 26 | SEKHRI PAUL J | other | 140,000 |
| Sep 22, 25 | AKKARAJU SRINIVAS | other | 983,214 |
| Sep 22, 25 | AKKARAJU SRINIVAS | other | 877,214 |
| Sep 22, 25 | AKKARAJU SRINIVAS | other | 106,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VTVT coverage
Recent articles, reports, and earnings notes.
Want a deeper read on VTVT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jul 2
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jun 2
vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable
zacks.com · May 15
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · May 13
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · May 8
vTv Therapeutics to Participate in Upcoming May Investor Conferences
globenewswire.com · May 7
Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?
zacks.com · Apr 20
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Apr 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Bullish or bearish?
Where do you stand on VTVT?